MedTrace Logo

Prevalence of COVID-19 in High Altitude : Insights From the Highest City of the World

NCT04604249 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2021-02-04

No results posted yet for this study

Summary

Since the beginning of 2020, SARS-CoV-2 outbreak spread over the world, conducting in a pandemic state declared by the world health organization in March 2020. Conflicting data have been yet published regarding to the incidence rate of COVID-19 infection in altitude. Mainly based on analysis from national Peru database, some authors argued that COVID-19 disease, as well as case fatality rate was less frequent in altitude. However, epidemiological data are lacking regarding to the prevalence of COVID-19 in altitude, and more specially in high altitude.

Aim of this cross-sectional study is to assess the prevalence of seroconversion for the SARS-CoV-2 in the population of La Rinconada, a mining town at 5,100 m, the highest city in the world.

Conditions

  • Covid19
  • High Altitude

Interventions

DIAGNOSTIC_TEST

SARS-CoV-2 rapid diagnostic test (COVID-PRESTO® IgM/IgG, AAZ, Boulogne-Billancourt, France)

Presence of specific SARS-CoV-2 antibodies (IgM or IgG).

Sponsors & Collaborators

  • Centre d'Expertise sur l'Altitude EXALT

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-26
Primary Completion
2021-11-30
Completion
2021-12-31

Countries

  • Peru

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04604249 on ClinicalTrials.gov